Acurx Pharmaceuticals Announces Successful Completion and Early Discontinuation of the Ibezapolstat Phase 2b Trial for Treatment of C. difficile Infection Oct 2, 2023
Acurx Announces Presentation and Update of Its pol IIIC R&D Pipeline at the World Antimicrobial Resistance Scientific Congress Sep 12, 2023
Acurx Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference September 11-13, 2023 Aug 22, 2023
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2023 Results and Provides Business Update Aug 14, 2023
Acurx Pharmaceuticals to Discuss Second Quarter 2023 Financial Results and Provide Business Update Jul 24, 2023
Acurx Pharmaceuticals to Participate in the Maxim Group LLC Virtual Healthcare Conference on Tuesday, June 20, 2023 to Thursday, June 22, 2023 at 9 am ET Jun 15, 2023
Acurx Pharmaceuticals, Inc. Announces Pricing of $4.0 Million Registered Direct Offering May 16, 2023
Acurx Pharmaceuticals, Inc. Reports First Quarter 2023 Results and Provides Business Update May 12, 2023
Acurx Pharmaceuticals to Discuss First Quarter 2023 Financial Results and Provide Business Update May 5, 2023
